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vidence-based medicine (EBM), 
a process of accurately assessing 
and integrating the weight 
carried by various levels of available 
evidence, (e.g., randomized controlled 
trials [RCTs], case-control studies, case 
series, and expert opinion) has become 
the cornerstone of good medical 
practice. The RCT is considered the 
“gold-standard” of EBM, but, while 
the RCT may indeed be the most 
statistically unbiased method of 
assessing an intervention, it can also 
have limitations and must be correctly 
interpreted, aided by other forms of 
evidence. 
    In addition, in certain ﬁ  elds of 
medicine, such as management of 
patients with severe sepsis, this “high-
grade” RCT evidence is in short supply 
[1]. The heterogeneous nature of the 
intensive-care-unit (ICU) population 
and the complexity of the disease 
processes involved make it difﬁ  cult to 
show the impact of acute interventions 
on long-term outcomes in this setting. 
In addition, many treatment strategies 
are life saving (such as mechanical 
ventilation in respiratory failure, blood 
transfusions in acute hemorrhage, and 
administration of vasopressor agents in 
severe shock), and could not ethically be 
studied in a placebo-controlled RCT [1]. 
    In view of these uncertainties, it is 
difﬁ  cult to provide guidelines for the 
management of the patient with sepsis. 
Yet severe sepsis is a serious health-care 
problem, affecting some 30% of ICU 
admissions and associated with ICU 
mortality rates of around 30%; septic 
shock is associated with ICU mortality 
rates of around 50%. There is no doubt 
that better outcomes could be achieved 
in this patient population. 
  Current  Guidelines
    The American College of Critical 
Care Medicine recently developed 
guidelines for the management of the 
hemodynamically unstable patient with 
sepsis [2]. More general guidelines 
were produced by the Surviving 
Sepsis Campaign by using a modiﬁ  ed 
Delphi methodology with a group of 
about 50 international critical care 
and infectious disease experts [3]. All 
aspects of management of the patient 
with severe sepsis were covered (Box 
1), and recommendations, graded 
from A to E depending on the level 
of evidence available, were developed 
for each category. However, these 
guidelines and their application have 
generated much debate. A closer 
look at the Surviving Sepsis Campaign 
guidelines shows the low level of 
conﬁ  dence that the authors have in 
the evidence behind the interventions: 
most interventions were only given an E 
grade (Figure 1). 
    Limitations to Guidelines for the 
Management of the Patient with 
Sepsis
    There are many reasons why EBM 
may be particularly difﬁ  cult to apply, 
and hence result in somewhat limited 
guidelines, in the management of 
patients with severe sepsis. I have 
selected just three possible reasons 
below, drawing examples from the 
Surviving Sepsis Campaign guidelines 
to illustrate each point. 
    No RCT Evidence Available
    There are many areas in the 
management of the patient with severe 
sepsis that have never been subjected 
to RCTs, and recommendations must 
be based on other grades of evidence. 
Here I give just two examples.
      Antibiotic therapy.   The beneﬁ  cial 
effects of antibiotic therapy, per se, 
have never been speciﬁ  cally tested in 
an RCT, although RCTs have been 
conducted that compare different 
antibiotics in various speciﬁ  c infections. 
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  Box 1. Aspects of Patient 
Management Covered by the 
Surviving Sepsis Campaign 
Guidelines
  •  Initial  resuscitation
  •  Diagnosis
  •  Antibiotic  therapy
  •  Source  control
  •  Fluid  therapy
  •  Vasopressors
  •  Inotropic  therapy
  •  Steroids
  •  Activated  protein  C
  •  Blood  product  administration
  •  Mechanical  ventilation
  •  Sedation/analgesia
  •  Glucose  control
  •  Renal  replacement
  •  Bicarbonate  therapy
  •  Deep-vein  thrombosis  prophylaxis
  •  Stress-ulcer  prophylaxis
    •  Consideration for limitation of life 
support 
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The only recommendation that 
is supported by clinical studies is 
that antibiotics that cover all likely 
organisms should be prescribed 
[4–7]. It also seems logical that if 
antimicrobial therapies are effective, 
they should be started as early as 
possible. However, it is difﬁ  cult to 
administer agents that can cover all 
possible organisms in every case; should 
we, for example, treat a patient who 
has pneumonia that is likely a result 
of   Pneumococcus   with broad-spectrum 
antibiotics? In addition, should empiric 
antibiotics be administered to all 
patients with suspected infection, so 
that patients who are infected have the 
beneﬁ  t of receiving early therapy, or 
should we wait until infection is proven 
in order to limit the negative effects 
and costs of unnecessary antimicrobial 
treatment?
      Vasoactive agents.   Many patients 
with septic shock will need vasopressor 
agents, but which agent is best? 
Dopamine has inotropic properties in 
addition to its vasopressor effects, thus 
creating a sort of “inoconstricting” 
agent, and its dopaminergic effects 
may preferentially direct blood ﬂ  ow 
to the kidneys and the gut, although 
admittedly, this does not prevent 
renal failure [8]. On the other 
hand, norepinephrine may have 
beneﬁ  cial effects on renal function 
during sepsis [9]. Epinephrine is 
also used routinely in some centers. 
No RCT has directly compared 
these agents in patients with severe 
sepsis. A multicenter French study 
evaluating the effects of epinephrine 
versus the effects of a combination 
of norepinephrine with dobutamine 
has been completed recently; there 
was no difference in mortality in the 
two groups (D. Annane, unpublished 
data). A multicenter RCT comparing 
norepinephrine with dopamine as 
ﬁ  rst-line vasopressors in septic shock is 
currently underway in Europe.
    RCT Evidence Available, but Not 
Speciﬁ  cally in Patients with Sepsis
    There are interventions that may be 
relevant to patients with sepsis and 
that have undergone testing in RCTs, 
but these RCTs were not conducted 
speciﬁ  cally in patients with sepsis. 
Instead, they were conducted in 
general populations of ICU patients, 
some of whom may have had a 
diagnosis of sepsis. Extrapolation 
of these results in general, or from 
subgroup analyses, can lead to 
recommendations, but are such 
recommendations really relevant to the 
patient with sepsis?
      Fluid administration.   The optimal 
ﬂ  uid for resuscitating the patient with 
septic shock is a controversial topic. 
Although there is no evidence that 
colloids are any better than crystalloids, 
there is a strong rationale to attempt 
to limit the formation of edema. The 
large Saline versus Albumin Fluid 
Evaluation (SAFE) study in Australasia, 
which compared albumin and saline 
in patients in intensive care, showed 
similar outcomes with these two 
different ﬂ  uids at 28 days [10]. But in 
the subgroup of patients with severe 
sepsis, 185 (30.7%) of the 603 patients 
with severe sepsis who had been 
assigned to receive albumin died, and 
217 (35.3%) of the 615 patients with 
severe sepsis who had been assigned to 
receive saline died (relative risk, 0.87; 
95% conﬁ  dence interval, 0.74–1.02;   p   
= 0.09). Hence, there was a suggestion 
that albumin may be associated with 
improved outcomes in this population 
of patients, but subgroup analyses carry 
many limitations, including reduced 
statistical power, and reliance on such 
results may be erroneous [11]. Further 
studies are necessary that speciﬁ  cally 
target patients with severe sepsis and 
septic shock, and that take the severity 
of hypoalbuminemia into account.
      Tight blood sugar control.   Van 
den Berghe et al. [12] showed that 
patients in the surgical ICU who 
received intensive insulin therapy 
(to maintain blood glucose levels at 
80–110 mg/dl) had reduced mortality 
compared with those who were 
managed conventionally (infusion 
of insulin only if blood glucose levels 
exceeded 215 mg/dl). The reduction 
was greatest for deaths caused by 
multiple-organ failure with a proven 
septic focus. Although compelling 
and potentially important for patients 
with sepsis, these observations were 
made in a single institution, and were 
not speciﬁ  cally targeted at patients 
with sepsis. In addition, maintaining 
tight blood sugar control can be a 
challenge for staff, especially since 
the risk of hypoglycemia is of great 
concern in unstable patients with 
sepsis. A recent multicenter study in 
Germany was discontinued prematurely 
because of identical mortality rates in 
the treatment groups and a greater 
incidence of hypoglycemia in the 
tight blood sugar group (K. Reinhart, 
unpublished data).
      Blood transfusions.   In 838 
critically ill patients, Hebert et al. 
[13] randomized patients to receive 
a restrictive transfusion strategy, 
maintaining hemoglobin levels at 
7–9 g/dl, or a more liberal approach 
DOI: 10.1371/journal.pmed.0030346.g001
  Figure 1.   Number of Recommendations of Each Grade of Evidence in the Surviving Sepsis 
Campaign Guidelines   
  The  ﬁ  gure shows that there are more E-grade recommendations than all the other grades put 
together. Grading system: A, supported by at least two large randomized trials with clear results; B, 
supported by a large randomized trial with clear results; C, supported by small randomized trial(s) 
with uncertain results; D, supported by a study with nonrandomized contemporaneous controls; E, 
studies with historical controls, uncontrolled studies, case series, and expert opinion.  
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with hemoglobin levels maintained at 
10–12 g/dl. The restrictive approach 
was at least as effective as the liberal 
approach and perhaps more so in 
younger and less severely ill patients. 
However, this study again included 
a general population of critically 
ill patients and was not focused 
speciﬁ  cally on patients with sepsis. In 
addition, although the observational 
Anemia and Blood Transfusion in 
the Critically Ill (ABC) study [14] 
supported the suggestion that higher 
transfusion rates were associated 
with increased mortality, the recent 
Sepsis Occurrence in Acutely Ill 
Patients (SOAP) study [15] found no 
association between transfusion and 
mortality. Moreover, Rivers et al. [16] 
showed that patients in an early goal-
directed therapy group, with increased 
survival rates, were more likely to have 
received transfusions. 
    How do we account for these 
apparent differences? Perhaps they are 
related to a change in the quality of 
transfusion since the original Hebert 
study [13], for which the ﬁ  rst data were 
collected almost ten years ago. Indeed, 
since that study, deleukocytation of 
blood is now routine practice in many 
countries and leukoreduced blood 
has been shown to be associated with 
reduced mortality [17]. A large study 
by the SOAP collaboration is under 
way in Europe to reevaluate transfusion 
thresholds in a heterogeneous group of 
critically ill patients. 
    RCT Results Available, but 
Questions Remain
      Mechanical ventilation.   An important 
study conducted by the Acute 
Respiratory Distress Syndrome (ARDS) 
Network [18] in 861 patients with 
acute lung injury (ALI) or ARDS was 
stopped at interim analysis, as patients 
who were randomized to mechanical 
ventilation with “low” tidal volumes of 6 
ml/kg had a lower mortality rate than 
those ventilated with tidal volumes of 
12 ml/kg. At face value, therefore, this 
study provides strong evidence that 
patients with ALI and ARDS should 
be ventilated with low tidal volumes. 
However, only two tidal volumes were 
compared and the high tidal volume 
chosen for the study was somewhat 
higher than the values usually applied 
[19]. Hence, the results of this study do 
not necessarily mean that all patients 
should be ventilated with tidal volumes 
of 6 ml/kg, but rather that ventilating 
patients at volumes of 12 ml/kg is 
detrimental. In addition, whether these 
results apply to all patients with severe 
sepsis, even when they do not meet 
the criteria for ALI/ARDS, has not yet 
been established. 
      Steroids.   Steroid administration 
in septic shock has been a matter 
of debate for several decades. The 
administration of large boluses of 
methylprednisolone was not shown to 
be beneﬁ  cial in large controlled studies 
[20,21]. More recently, the concept of 
relative adrenal insufﬁ  ciency has led 
to the consideration of administering 
moderate doses of steroids (200  –300 
mg/day of hydrocortisone) in septic 
shock. But a multicenter RCT [22] 
comparing moderate dose steroids 
with placebo failed to show signiﬁ  cant 
differences in survival rates in the initial 
analysis. Complex statistical calculation 
was needed to show only a trend 
for improved outcome in the global 
population, although the differences 
became statistically signiﬁ  cant in 
patients with an abnormal response to 
a 250-µg cosyntropin test. 
    Nevertheless, other recent studies 
have suggested improved outcomes in 
patients with septic shock who received 
moderate doses of hydrocortisone, 
so that its use is recommended in 
the Surviving Sepsis guidelines [3]. 
But should all patients with septic 
shock receive this regimen? Some 
experts use a 250-µg cosyntropin test 
to identify patients who could beneﬁ  t 
more from steroid administration 
[22]; others suggest that single cortisol 
measurements may be sufﬁ  cient [23]. 
And still others have proposed that a 
1-µg test may be more physiological 
[24], and some suggest that no 
measurements can be interpreted 
adequately. So, there is clearly no 
consensus on this issue.
      Drotrecogin alfa (activated).   Despite 
many years of research, only one 
agent—drotrecogin alfa (activated)—
has been identiﬁ  ed that speciﬁ  cally 
affects the sepsis response and by 
doing so improves survival [25]. The 
efﬁ  cacy of the drug has been shown 
in a large RCT, the Recombinant 
Human Activated Protein C 
Worldwide Evaluation in Severe Sepsis 
(PROWESS) study [25], and has been 
supported by the open-label Extended 
Evaluation of Recombinant Human 
Protein C (ENHANCE) study [26]. Yet, 
despite the RCT evidence, some people 
still challenge the efﬁ  cacy of the drug 
[27], fueled further by the negative 
results of the recent Administration 
of Drotrecogin alfa (activated) in 
Early Stage Severe Sepsis (ADDRESS) 
study [28] conducted in patients with 
severe sepsis but with a low risk of 
death. Drotrecogin alfa (activated) is 
therefore licensed for adult patients 
at “high risk of death,” and one of the 
problems is how best to categorize such 
patients. 
    The Food and Drug Administration 
suggests that the APACHE II score 
(http:⁄⁄www.sfar.org/scores2/
apache22.html) may be used, with 
treatment restricted to patients with 
an APACHE II score greater than 25. 
But this may not be the most reliable 
method for choosing patients for 
several reasons, including the following: 
(1) the use of drotrecogin alfa 
(activated) has not been validated in 
this context; (2) there is considerable 
variability in the calculation of this 
score [29,30]; and (3) age is included 
in the APACHE II score, making it 
more likely that elderly patients meet 
the criteria for administration than 
younger patients. Criteria for choosing 
patients that are based on organ 
failure may be more effective, but 
further study is necessary to optimize 
the use of this drug. The results of 
data analysis from an integrated 
database (INDEPTH) of placebo and 
drotrecogin alfa–treated patients from 
ﬁ  ve severe sepsis trials have recently 
been published that support a survival 
beneﬁ  t associated with drotrecogin alfa 
(activated) treatment compared with 
placebo [31]. 
  Conclusion
    Many uncertainties remain within 
the ﬁ  eld of intensive-care medicine, 
and in sepsis in particular. EBM 
has been promoted as the way to 
practice medicine, but in some 
patient groups—for example, patients 
with sepsis—EBM can be difﬁ  cult to 
apply. Recently developed guidelines 
reﬂ  ect this problem with very few 
recommendations being supported 
by the highest level of evidence. The 
results of ongoing and future trials 
will expand the evidence base, and 
current guidelines need to be adapted 
accordingly to ensure that patients 
continue to be treated with the very 
latest and best standard of care.  
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